Core-binding factor: a central player in hematopoiesis and leukemia.

Area of Science:

• Hematology
• Molecular Biology
• Genetics

Background:

• Chromosomal rearrangements are common in hematopoietic tumors.
• These rearrangements often disrupt genes critical for blood cell development.
• Core-binding factors (CBFs) are transcription factors essential for hematopoiesis.

Purpose of the Study:

• To investigate the role of core-binding factor (CBF) genes (CBFA2 and CBFB) in hematopoietic development and their disruption in tumors.
• To understand how chromosomal rearrangements involving CBFA2 and CBFB lead to the formation of transdominant negative inhibitors.
• To elucidate the impact of these disruptions on hematopoiesis at different developmental stages.

Main Methods:

• Analysis of chromosomal rearrangements in hematopoietic tumors, specifically t(8;21), t(12;21), and inv(16).
• Identification of disrupted genes: CBFA2 (encoding CBFalpha) and CBFB (encoding CBFbeta).
• Investigation of the functional consequences of chimeric proteins generated by these rearrangements.

Main Results:

• Chromosomal rearrangements t(8;21) and t(12;21) disrupt the CBFA2 gene.
• The inv(16) rearrangement disrupts the CBFB gene.
• Both CBFA2 and CBFB are essential for definitive hematopoiesis in mice, required for hematopoietic stem cell emergence.
• Transdominant negative inhibitors created by rearrangements can block hematopoietic cell emergence during embryogenesis.
• Leukemic translocations involving CBFA2 and CBFB disrupt hematopoiesis at later stages than embryonic stem cell emergence.

Conclusions:

• Core-binding factor genes CBFA2 and CBFB are crucial for the earliest stages of definitive hematopoietic stem cell development.
• Disruptions in CBFA2 and CBFB, leading to transdominant negative inhibitors, contribute to leukemogenesis by impairing hematopoiesis.
• These genes are also required for later stages of hematopoietic lineage differentiation.